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Abstract
Kawasaki disease is an acute febrile condition seen in children. However, it is also well recognized
that some patients do not fulfill the classic diagnostic criteria for the diagnosis of kawasaki disease.
The incomplete form of kawasaki disease is termed as ‘Incomplete KD’ or ‘Atypical KD’. We present
a case of a 6 year old child with a history of prolonged fever, periorbital, oral and lip changes, changes
in the extremities and an erythamatous, maculopapular rash. Based on the physical exam and her
echocardiogram that showed right coronary artery dilatation, Intravenous immune globulin was
administered in this patient. This patient was refractory to two doses of intravenous immune globulin
and therefore was started on methylprednisolone, to which she responded dramatically. The
diagnostic dilemma primarily arose when this child presented with joint pain a day after her discharge
from the hospital and a positive laboratory workup. So, was this a case of incomplete Kawasaki
refractory to intravenous immuno globulin therapy or systemic juvenile idiopathic arthritis? We
suggest that physicians should be cognizant of the fact that they must individualize every patient’s
management to the best of their knowledge and judgment, rather than merely going by the guidelines.
Case presentation
A 6 years and 4 months old girl from Karachi, Pakistan
presented with a 15 days history of fever, sore throat, dry
and cracked lips, rash and peri-orbital swelling. The fever
was high grade, intermittent and associated with chills and
rigors. The rash was erythematous and patchy in distribu-
tion with involvement of the face and limbs. There was
swelling on the body which was initially peri-orbital and
then became more generalized to involve the extremities.
She also had a history of reduced oral intake since the
past ten days. Associated complaints included arthralgia
without ostensible arthritis, diarrhea and several episodes
of vomiting. Before coming to our hospital, she had been
treated with amoxicillin, lincomycin, cefixime and clari-
thromycin for a week by a local physician without any
improvement in signs or symptoms. She had received all
her vaccinations as per EPI (extended program for
immunization) schedule of Pakistan.
On examination, she had an irritable and toxic look with
bilateral peri-orbital swelling and cracked lips. A straw-
berry tongue was seen on examination of the buccal cavity.
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An erythematous, maculopapular rash on the face and
limbs was observed. Edema and induration of the limbs
was also appreciated. No evidence of cervical lymphade-
nopathy or conjunctival injection was noticed (Figure 1).
She was tachcardiac with a pulse of 160 beats per minute,
febrile with a temperature of 39°C. Her blood pressure
was 105/66 mmHg.
With this history and presentation, the initial impression
was of cellulitis, an acute hypersensitivity reaction or an
incomplete kawasaki disease. She was admitted for
observation and administered intravenous fluids and
antibiotics (ceftriaxone and cloxacillin). Her baseline
laboratory work up was sent. Abnormal laboratory
findings included a low hemoglobin (9.3), a low hemato-
crit (28%), raised white cell count (38.4 × 109/L), with a
predominance of neutrophils (83.4%), and thrombocyto-
sis (platelet count of 925). C-reactive protein and
Erythrocyte Sedimentation Rate were raised (24.4 mg/dl
and 100mm/hr respectively). Albumin was lower than the
normal range of 1.6 mg/dl. The rest of the work-up
including electrolyte and renal function workup was
within the normal range.
In addition, her blood cultures showed no growth, her
urine detailed report was normal and her liver function
tests showed no abnormalities.
An echocardiogram was performed which showed a small
patent foramen ovale (PFO), a normal left coronary artery
and right coronary artery dilatation with thrombus
formation; with ostium measurements of 5.7 - 6.2 mm
and measurements in the remaining artery between 3.2 -
4 mm (Figure 2).
Based on the constellation of these findings, a diagnosis of
incomplete kawasaki disease was made. She was given
intravenous immunoglobulins (IVIG - 2 gm/kg), aspirin
(100 mg/kg/day) and acetaminophen as needed. How-
ever, the response to this management was sub-optimal.
She continued to have persistent fever spikes; even after
> 36 hours of the completion of the first dose of IVIG and
her inflammatory markers remained elevated with a
C-reactive protein of 25 mg/dl and platelet count of
1365 × 109/L. She was then given a second dose of IVIG.
Her autoimmune profile was also sent at this stage which
was negative (ANA, ASMA, AMA). She was given pulse
therapy with intravenous methylprednisolone for three
days after her failure to respond to the second dose of
IVIG. In addition, she received clopidogerel, aspirin,
ceftriaxone and vancomycin. She showed significant
clinical improvement after institution of steroid therapy
with resolution of fever spikes and normalization of
inflammatory markers (ESR = 55, CRP = 3.7 and plate-
let = 660 × 109/L). Repeat echocardiography showed no
change as compared to previous study.
During the hospital stay, she developed the complaint of
generalized abdominal pain. An ultrasound of the abdo-
men was performed which showed mild hepatomegaly
with some echogenic areas in the renal parenchyma in
both kidneys. This most likely represented protein casts.
She was discharged from the hospital on the 13th day of
Figure 1. 6 years old girl with peri-orbital erythema and
swelling, cracked lips, swelling and rash of extremities.
Figure 2. Echocardiographic images showing right coronary
artery dilatation.
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admission on proton pump inhibitors, clopidogerel and
aspirin.
However, one day after her discharge from the hospital,
she returned to the emergency room with complaints of
high grade fever and backache for one day. On examina-
tion, she had arthritis of the right knee joint and right hip
joint. No abnormalities of the palms, soles and oral
mucosa were noted and no rash or desquamation was
seen. She was admitted and started on intravenous fluids,
antibiotics and NSAIDs for relief of arthritis. Anti-nuclear
antibody and Rheumatoid Factor were also sent which
came back to be borderline high. An aortogram was also
done to better visualize the coronary arteries; dilatation of
the right coronary artery was not seen on this study. A
diagnosis of evolving Systemic Juvenile Idiopathic Arthri-
tis was made because of the short time duration (< 6
weeks). She was started on steroids, proton pump
inhibitor, naproxen and clopidogerel and discharged
after an uneventful stay of 6 days. Her follow-up in the
clinic after a week showed improvement with a CRP of 0.3
mg/dl, platelets of 668 × 109/L, ESR = 5 mm/hr and
Hemoglobin of 13.6 g/dl).
She has been improving clinically over the last few
months. All her recent follow ups have been unremarkable
in terms of any fever, joint pain, swelling or limitation of
activity. The child is healthy, active and playful with no
active complaints. Her systemic exams have also been
unremarkable so far. Her last EDSR and CRP were within
the normal range. She has been off steroids since the last
month. She was started on 4 tablets of prednisone, which
has been tapered down to zero over the last five months.
Her current therapy comprises of Tab Naproxen Sodium
(once daily).
Discussion
Kawasaki disease (KD) is an acute febrile condition seen
in children. Even though it was first reported in Japan
about 30 years ago, the original diagnostic criteria defined
by Dr Tomisaku Kawasaki in 1967 are still authentic and
widely used today. However, it is also well recognized that
some patients do not fulfill the classic diagnostic criteria
for the diagnosis of KD. The incomplete form of KD is
termed as ‘Incomplete KD’ or ‘Atypical KD’. Because
incomplete KD is not a mild form of KD, children remain
at similar risk for cardiovascular sequelae as that of
complete KD [1]. Since the disease has a similar risk of
coronary artery abnormalities (CAA) as complete KD
[2-5], it is necessary to make an accurate diagnosis in order
to prevent the development of coronary artery abnormal-
ities CAA [1-4]. “Incomplete” KD is the preferred term, as
these patients do not appear to differ from those with
classic KD in any way except that they lack a sufficient
number of criteria to fulfill the epidemiologic case
definition [5]. The American Heart Association guidelines
have been used for the diagnosis of incomplete KD, which
is based on echocardiographic findings and laboratory
findings [6].
Cervical lymphadenopathy is the cardinal manifestation
most often absent in children with incomplete KD as was
observed in our patient [1], this is followed by rash,
peripheral extremity and mucous membrane changes [7].
Because of the prolonged unexplained history of fever, the
typical age group of the patient and the rash, incomplete
KD was considered in our patient.
The guidelines for the evaluation and treatment of patients
in whom incomplete KD is suspected were established by
the American Heart Association in 2004. [6] Our patient
had a 15 day history of fever and three of the principal
clinical criteria. Clinical signs and symptoms were
consistent with KD. According to the algorithm of the
guidelines, assessment using laboratory tests was required
[1]. The tests showed that the patient had a C-reactive
protein level of ≥3.0 mg/dL and fulfilled ≥3 supplemental
laboratory criteria (albumin ≤3.0 g/dL, anaemia for age,
platelets after 7 days ≥45 × 104/μL, WBC counts ≥15 000/
μL and urine ≥10 WBCs/ high-power field). Therefore, we
considered this patient to be suffering from incomplete
KD.
She was administered the first dose of IVIG, keeping in
mind her clinical presentation and laboratory parameters.
Data supports the use of IVIG while there is ongoing
inflammation (usually taken as ongoing fever or raised
acute inflammatory markers. One high quality systemic
review of sixteen RCTs showed that IVIG is of benefit in
treating kawasaki disease. [19]. In children with fever and
classic clinical and laboratory findings of KD, treatment
with IVIG resulted in better coronary outcomes and
decreased the total length of time of clinical symptoms
[20].
Immunosuppressive therapy was administered in this case
to control the symptoms after two doses of refractory IVIG
treatment. There could be two considerations in the light
of the stated scenario. It could have been a case of
incomplete KD that was refractory to IVIG therapy,
responding later to methyl prednisolone. Failure to
respond usually is defined as persistent or recrudenscent
fever more than 36 hours after completion of the initial
IVIG infusion [8]. The infusion of intravenous immuno-
globulin (IVIG) within 10 days of the onset of KD is
known to reduce both the duration of fever and the
incidence of coronary artery disease, and thus together
with aspirin are the standard treatment [9,10]. However,
approximately 15-20% of the children with KD have a
persistent or recurrent fever and a progression of coronary
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dilatation despite IVIG treatment [8,11,12]. Studies sup-
port the use of corticosteroids in most patients with IVIG-
refractory KD [13,14]. Wright et al first described the
outcome in patients with IVIG-resistant KD who were
treated with pulsed doses of corticosteroid. All the patients
were treated successfully with pulse methylprednisolone
with no adverse effects noted. A recent review article
suggests that pulse methylprednisolone therapy should be
considered if there is no response to two standard doses of
IVIG treatment [15].
The other possibility is that this was a case of an evolving
systemic juvenile idiopathic arthritis (SJIA), given the less
than 6 week presentation, with fever, arthritis, rash and a
positive lab workup. The main dilemma is that neither KD
nor SJIA have absolutely specific diagnostic laboratory
tests. Both diseases show similar laboratory findings with
elevated WBC counts, elevated C-reactive protein, leuko-
cytosis, thrombocytosis and anaemia and these account
for diagnostic confusion. Moreover, the initial presenta-
tion of SJIA appears similar to incomplete KD. Prolonged
fever and erythematous rash are common findings in both
incomplete KD and SJIA [16]. These findings suggest that
SJIA cannot be easily distinguished from incomplete KD.
In our case, the clinical and diagnostic dilemma primarily
arose when the patient presented with joint pain a day
after her discharge from the hospital and a positive
laboratory workup [16].
The echocardiogram plays a key role in making a
diagnosis of incomplete KD. However, aneurysms rarely
form before the 10th day of illness [17,18]. However,
instituting IVIG therapy within the first 10 days of illness is
recommended [16].
Therefore, physicians are always in a dilemma over
whether to first make an accurate diagnosis or begin
early treatment to prevent the development of CAA. IVIG
therapy is not only a costly intervention but it also exposes
the patients to unnecessary risks related to receiving a
blood product [18], the diagnosis of incomplete KD
requires sufficient clinical evidence. Although an aorto-
gram done later in our patient showed no abnormal
findings, her clinical features, laboratory findings and
echocardiographic findings were sufficiently strong evi-
dence to warrant a working diagnosis of incomplete KD
and therefore IVIG was administered.
It is important to recognize that as long as the diagnosis of
KD is based upon clinical criteria, it will remain a deficient
undertaking. As long as the disadvantages of under-
treating appear to outweigh the disadvantages of over-
treating, IVIG will be used injudiciously to treat these
children. However, this approach of treating children at
risk even though the diagnosis is uncertain should result in
fewer children with incomplete KD going untreated and
subsequently developing coronary artery aneurysms.
Hopefully, with increasing knowledge, diagnostic accuracy
will improve over time, thereby ensuring that proper
therapy is instituted correctly in patients with KD and SJIA.
Conclusion
We have presented here a case causing considerable
diagnostic dilemma. Physicians need to recognize that
systemic-onset juvenile idiopathic arthritis can be mis-
taken for incomplete kawasaki disease, despite the use of
established guidelines.
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